



Date: 07th July, 2021.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir,

Ref : Script Id "BAJAJHCARE", Script Code "539872".
Sub : Business Updates- The Company gets license from Defence Research and Development Organisation (DRDO) to manufacture and market "2-Deoxy-D-Glucose" (2-DG), used in control & treatment of Covid-19.

In terms of regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates - The Company gets license from Defence Research and Development Organisation (DRDO) to manufacture and market "2-Deoxy-D-Glucose" (2-DG), used in control & treatment of Covid-19.

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of
Bajaj Healthcare Limited

Aakash Kesari
Company Secretary

BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

BHL gets license from Defence Research and Development Organisation (DRDO) to manufacture and market "2-Deoxy-D-Glucose" (2-DG), used in control & treatment of Covid-19.

Thane, 07th July, 2021: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has received a licence from DRDO to Manufacture and Market of "2-Deoxy-D-Glucose" (2-DG) as approved medication for the treatment of COVID-19 patients.

2-Deoxy-D-Glucose" (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVI D-19 patients as an adjunct therapy to the existing standard of care.

Commenting on license received from DRDO for "2-Deoxy-D-Glucose", Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said *"We are pleased to add 2-Deoxy-D-Glucose to our growing product portfolios after receiving license from DRDO. The second waves of coronavirus is more aggressive and bigger in number than the first. Our countries medical infrastructure is really struggling with scarcity of oxygen capacities. We hope the availability of an effective treatment such as 2-Deoxy-D-Glucose (2-GD) will considerably ease the pressure and offer patients much needed and timely therapy option. Most patients ailing from moderate to severe symptoms can benefit from the use of Deoxy-D-Glucose."*

The Defence Research and Development Organisation (DRDO) has granted permissions to manufacture and market the **"2-Deoxy-D-Glucose"** in the domestic market.

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Krunal Shah/ Vinayak Shirodkar

Captive IR Strategic Advisors Pvt. Ltd.

Contact: +91 98922 88895

Email: krunal@cap-ir.com / Vinayak@cap-ir.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE